EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation



Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation



Transplantation 58(4): 437-442



We analyzed the treatment of acute GVHD following allogeneic, related or unrelated donor bone marrow transplantation (BMT). Of 510 patients transplanted between January 1986 and July 1991, 272 (53.0%) developed acute GVHD. Patients (n = 240) received treatment with either corticosteroids (n = 209), antithymocyte globulin (ATG)/prednisone (n = 26), or an anti-T cell immunotoxin (n = 5). After 28 days, 33% (79/240) had achieved a response to primary therapy; 24% a complete response. Ninety-five patients received 1 or more courses of salvage immunotherapy and 26 (27%) responded. In multivariate analysis, a response to primary therapy was the single most important factor independently predicting a lower risk of subsequent chronic GVHD (P < .0001) and improved long-term survival (P = .01). The GVHD clinical stage score, which we previously described, had significant predictive value for response to therapy and freedom from chronic GVHD. The conventional clinical grade had no such predictive value. In multivariate analysis, transplantation from a mismatched or an unrelated donor was not of independent importance in predicting either acute GVHD treatment response or chronic GVHD. However, these alternative donor transplants led to poorer survival. This analysis identifies patient subsets having GVHD with a low likelihood of response to conventional immunosuppressive treatment and may be used to indicate those needing early application of more intensive therapy. More important, however, the overall low response rates observed suggest that more effective treatment for acute GVHD is still required to improve the results of transplantation therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 009673270

Download citation: RISBibTeXText

PMID: 8073512

DOI: 10.1097/00007890-199408270-00008



Related references

Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75(4): 1024-1030, 1990

Treatment of acute graft vs host disease gvhd with desferrioxamine dfo after allogeneic bone marrow transplantation. Nouvelle Revue Francaise d'Hematologie 31(6): 426, 1989

Association between TGF-beta expression and severe GVHD in allogeneic bone marrow transplantation. Transplantation Proceedings 33(1-2): 485-486, 2001

Anti-thymocyte globulin as part of the pretransplant conditioning regimen reduces severe acute GvHD and transplant-related mortality in CML patients undergoing allogeneic bone marrow transplantation. Annals of Hematology 73(SUPPL 2): A88, 1996

New approaches for amplification of graft vs leukemia gvl effects without severe gvhd in allogeneic bone marrow transplantation bmt. Journal of Cellular Biochemistry Supplement (12 PART C): 113, 1988

Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clinical Transplantation 23(1): 33-38, 2008

OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation. Journal of Clinical Immunology 2(3 Suppl): 148s-153s, 1982

Soluble c-kit levels in acute GVHD after allogeneic bone marrow transplantation. British Journal of Haematology 89(4): 897-899, 1995

Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study. Journal of Clinical Immunology 2(3 Suppl): 154s-157s, 1982

Allogeneic cell therapy for prevention of relapse in high risk acute leukemia following allogeneic bone marrow transplantation Control of GVHD by graded increments of donor lymphocyte infusion. Blood 88(10 SUPPL 1 PART 1-2): 418A, 1996

Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 108(7): 2485-2492, 2006

Allogeneic G-CSF stimulated bone marrow transplantation Results of the harvest, engraftment and acute GVHD. Blood 102(11): 967a, November 16, 2003

A metalloproteinase inhibitor prevents acute GVHD while preserving GVL effect of allogeneic bone marrow transplantation. Blood 92(10 SUPPL 1 PART 1-2): 292B, Nov 15, 1998

Influence of acute and chronic GVHD on the relapse rate after allogeneic bone marrow transplantation in childhood ALL and AML. Bone Marrow Transplantation 21(SUPPL 2): S83, April, 1998